학술논문
Finerenone: A new option for diabetic kidney disease.
Document Type
Article
Source
Subject
*DIABETIC nephropathies
*TYPE 2 diabetes
*MINERALOCORTICOID receptors
*CHRONIC kidney failure
*CHRONICALLY ill
*
*
*
*
Language
ISSN
1443-430X
Abstract
Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist that became available on the PBS in July 2023 for selected patients with chronic kidney disease and type 2 diabetes. It is indicated as an addition to standard care to delay progressive decline of kidney function and reduce the risk of cardiovascular mortality and morbidity in these patients. [ABSTRACT FROM AUTHOR]